Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. develops and commercializes drug-delivery technologies for subcutaneous administration of biologics and other injectable therapies. News about HALO commonly covers ENHANZE licensing agreements, Hypercon and Surf Bio hyperconcentration collaborations, partner product regulatory approvals, royalty-based revenue updates, and financial guidance.
The company also reports developments tied to its proprietary products Hylenex and XYOSTED, drug-device combination products using auto-injector technologies, and collaborations with pharmaceutical and biotechnology companies in oncology, inflammatory disease and other therapeutic areas.
Halozyme (Nasdaq: HALO) reported record second quarter 2026 results, with total revenue of $481.0 million, up 48% year-over-year, and royalty revenue of $307.7 million, up 50%. Adjusted EBITDA rose to $328.8 million from $225.5 million and GAAP diluted EPS increased to $1.90 from $1.33.
For full-year 2026, Halozyme raised guidance to total revenue of $1.835–$1.910 billion, royalty revenue of $1.220–$1.245 billion, adjusted EBITDA of $1.225–$1.280 billion, and Non-GAAP diluted EPS of $8.65–$9.00. The company signed five new ENHANZE and Hypercon agreements year-to-date and repurchased 4.8 million shares for $332.8 million in Q2 under its buyback programs.
Halozyme (Nasdaq: HALO) plans to release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the U.S. market close. The company will host a results conference call that day at 1:30 p.m. PT / 4:30 p.m. ET, with live access via pre-registration link and webcast replay available in the Investors section of its website.
Halozyme (Nasdaq: HALO) announced a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop additional subcutaneous formulations of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative neoplasms, using Halozyme's ENHANZE® drug delivery technology.
According to Halozyme, it will receive an upfront payment from Incyte, plus potential milestone payments and royalties on net sales of medicines using ENHANZE®. Incyte also receives an option to nominate up to two additional targets for use with ENHANZE®.
Halozyme (Nasdaq: HALO) appointed David Ramsay as President Drug Delivery, effective June 30, 2026. This is a newly created, enterprise-wide role.
Ramsay will drive growth of Halozyme's drug delivery technologies, set strategic priorities, and lead business development and alliance management, reporting to CEO Helen Torley.
Halozyme (Nasdaq: HALO) projects zero to minimal impact on its royalty revenue through at least 2035 from the newly released draft Medicare Drug Price Negotiation Program proposed rule. The company also projects no impact on its ability to sign new ENHANZE partnerships, supported by orphan drug protections and biosimilar-related provisions.
Halozyme (Nasdaq: HALO) reported strong Q1 2026 results and a new $1 billion share repurchase program, expecting at least $400 million of buybacks in 2026. Total revenue rose 42% year over year to $376.7 million, with royalty revenue up 43% to $240.7 million.
GAAP diluted EPS was $1.22 and non-GAAP diluted EPS $1.60. Halozyme reiterated 2026 guidance, including total revenue of $1.71-$1.81 billion, royalty revenue of $1.13-$1.17 billion, adjusted EBITDA of $1.125-$1.205 billion and non-GAAP EPS of $7.75-$8.25.
Halozyme (NASDAQ: HALO) announced a global collaboration and license agreement with GSK to apply Halozyme's ENHANZE® technology to develop subcutaneous formulations for multiple oncology targets, including antibody drug conjugates (ADCs).
GSK will pay an upfront fee, may pay future milestones, and Halozyme will receive royalties on net sales. The first clinical trial is projected to start in 2026, and the deal includes an option for additional targets.
Halozyme (Nasdaq: HALO) and Oruka (Nasdaq: ORKA) entered a global exclusive collaboration and license agreement dated May 6, 2026, granting Oruka rights to Halozyme's Hypercon™ microparticle technology for ORKA-001 (psoriasis) and an option for one additional target.
Terms include an upfront payment, potential future milestone payments, and mid-single digit royalties to Halozyme on net sales of Hypercon-enabled products.
Halozyme (Nasdaq: HALO) will report first quarter 2026 financial and operating results on Monday, May 11, 2026 after market close. A conference call is scheduled for May 11, 2026 at 1:30pm PT / 4:30pm ET.
According to Halozyme, the call requires pre-registration and will be available via live webcast and replay in the company's Investors section at www.halozyme.com.
Halozyme (Nasdaq: HALO) appointed Darren Snellgrove as Chief Financial Officer, effective June 8, 2026. Snellgrove brings more than 30 years of financial leadership, including roles leading investor relations at Johnson & Johnson and serving as CFO for J&J's Pharmaceuticals business, a unit generating over $50 billion in annual revenue.